Literature DB >> 16423059

Antibodies neutralizing feline leukaemia virus (FeLV) in cats immunized with the transmembrane envelope protein p15E.

Stefan Langhammer1, Janine Hübner, Reinhard Kurth, Joachim Denner.   

Abstract

The feline leukaemia virus (FeLV) vaccines that are currently in wide use are generally poor inducers of virus-neutralizing antibodies, although such antibodies appear after recovering from challenge. However, the presence of neutralizing antibodies in cats recovering from natural FeLV infection clearly correlates with resistance to subsequent infection and passive transfer of antibodies can protect other animals. After demonstrating the induction of neutralizing antibodies in rats and goats immunized with the transmembrane envelope protein p15E of FeLV, cats were immunized with the same antigen. High titres of neutralizing antibodies specific for FeLV were induced and epitope mapping revealed a pattern of recognition similar to that seen following immunization of rats and goats. These epitopes are highly related to epitopes recognized after immunization with porcine endogenous retrovirus (PERV) p15E and to epitopes recognized by neutralizing antibodies in patients infected with human immunodeficiency virus type 1. The ability of p15E to induce neutralizing antibodies in cats suggests that it should be included in the next generation of vaccines. In contrast, sera from FeLV-infected animals usually fail to recognize the neutralization-relevant epitopes in p15E. Since homologous epitope sequences are present in feline endogenous retroviruses, it appears that tolerance against these sequences is not induced.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16423059      PMCID: PMC1782217          DOI: 10.1111/j.1365-2567.2005.02291.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  22 in total

Review 1.  Feline leukaemia virus and vaccination.

Authors:  Andrew H Sparkes
Journal:  J Feline Med Surg       Date:  2003-04       Impact factor: 2.015

Review 2.  Progress towards the development of a HIV-1 gp41-directed vaccine.

Authors:  Georgia B McGaughey; Gaetano Barbato; Elisabetta Bianchi; Roger M Freidinger; Victor M Garsky; William M Hurni; Joseph G Joyce; Xiaoping Liang; Michael D Miller; Antonello Pessi; John W Shiver; Michael J Bogusky
Journal:  Curr HIV Res       Date:  2004-04       Impact factor: 1.581

3.  Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.

Authors:  Eve de Rosny; Russell Vassell; Shibo Jiang; Renate Kunert; Carol D Weiss
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

4.  Productive infection of human primary cells and cell lines with porcine endogenous retroviruses.

Authors:  V Specke; S Rubant; J Denner
Journal:  Virology       Date:  2001-07-05       Impact factor: 3.616

Review 5.  Antibodies: can they protect against HIV infection?

Authors:  C M Mc Cann; R J Song; R M Ruprecht
Journal:  Curr Drug Targets Infect Disord       Date:  2005-06

6.  Neutralizing antibodies against conserved domains of p15E of porcine endogenous retroviruses: basis for a vaccine for xenotransplantation?

Authors:  Uwe Fiebig; Oliver Stephan; Reinhard Kurth; Joachim Denner
Journal:  Virology       Date:  2003-03-15       Impact factor: 3.616

7.  Productive infection of a mink cell line with porcine endogenous retroviruses (PERVs) but lack of transmission to minks in vivo.

Authors:  V Specke; R Plesker; C Coulibaly; K Boller; J Denner
Journal:  Arch Virol       Date:  2002       Impact factor: 2.574

8.  Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates.

Authors:  Hana Golding; Marina Zaitseva; Eve de Rosny; Lisa R King; Jody Manischewitz; Igor Sidorov; Miroslaw K Gorny; Susan Zolla-Pazner; Dimiter S Dimitrov; Carol D Weiss
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  Virus safety in xenotransplantation: first exploratory in vivo studies in small laboratory animals and non-human primates.

Authors:  V Specke; H J Schuurman; R Plesker; C Coulibaly; M Ozel; G Langford; R Kurth; J Denner
Journal:  Transpl Immunol       Date:  2002-05       Impact factor: 1.708

10.  An endogenous retrovirus derived from human melanoma cells.

Authors:  Thomas Muster; Andrea Waltenberger; Andreas Grassauer; Sonja Hirschl; Peri Caucig; Ingrid Romirer; Dagmar Födinger; Heide Seppele; Oliver Schanab; Christine Magin-Lachmann; Roswitha Löwer; Burkhard Jansen; Hubert Pehamberger; Klaus Wolff
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

View more
  16 in total

1.  Immunization with hybrid proteins containing the membrane proximal external region of HIV-1.

Authors:  Nicola Strasz; Vladimir A Morozov; Jürgen Kreutzberger; Martina Keller; Magdalena Eschricht; Joachim Denner
Journal:  AIDS Res Hum Retroviruses       Date:  2014-02-07       Impact factor: 2.205

2.  Transspecies transmission of the endogenous koala retrovirus.

Authors:  Uwe Fiebig; Manuel Garcia Hartmann; Norbert Bannert; Reinhard Kurth; Joachim Denner
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  Sequence variation of koala retrovirus transmembrane protein p15E among koalas from different geographic regions.

Authors:  Yasuko Ishida; Chelsea McCallister; Nikolas Nikolaidis; Kyriakos Tsangaras; Kristofer M Helgen; Alex D Greenwood; Alfred L Roca
Journal:  Virology       Date:  2014-11-22       Impact factor: 3.616

Review 4.  Infection barriers to successful xenotransplantation focusing on porcine endogenous retroviruses.

Authors:  Joachim Denner; Ralf R Tönjes
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

Review 5.  Immunising with the transmembrane envelope proteins of different retroviruses including HIV-1: a comparative study.

Authors:  Joachim Denner
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

6.  Novel neutralising antibodies targeting the N-terminal helical region of the transmembrane envelope protein p15E of the porcine endogenous retrovirus (PERV).

Authors:  Alexander Waechter; Joachim Denner
Journal:  Immunol Res       Date:  2014-01       Impact factor: 2.829

7.  Detection of antibodies to the feline leukemia Virus (FeLV) transmembrane protein p15E: an alternative approach for serological FeLV detection based on antibodies to p15E.

Authors:  Eva Boenzli; Maik Hadorn; Sonja Hartnack; Jon Huder; Regina Hofmann-Lehmann; Hans Lutz
Journal:  J Clin Microbiol       Date:  2014-04-02       Impact factor: 5.948

8.  Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41.

Authors:  Rachel P J Lai; Jin Yan; Jonathan Heeney; Myra O McClure; Heinrich Göttlinger; Jeremy Luban; Massimo Pizzato
Journal:  PLoS Pathog       Date:  2011-12-15       Impact factor: 6.823

9.  Induction of neutralizing antibodies specific for the envelope proteins of the koala retrovirus by immunization with recombinant proteins or with DNA.

Authors:  Uwe Fiebig; Britta Dieckhoff; Christian Wurzbacher; Annekathrin Möller; Reinhard Kurth; Joachim Denner
Journal:  Virol J       Date:  2015-04-30       Impact factor: 4.099

10.  Increased titers of neutralizing antibodies after immunization with both envelope proteins of the porcine endogenous retroviruses (PERVs).

Authors:  Joachim Denner; Debora Mihica; Danny Kaulitz; Christa-Maria Schmidt
Journal:  Virol J       Date:  2012-11-05       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.